TRIFERIC AVNU 1.5 MG
IRON (FERRIC PYROPHOSPHATE CITRATE) : 1.5 MG · DIN 02515334 · ROCKWELL MEDICAL INC
Health Canada status: CANCELLED PRE MARKET
What is TRIFERIC AVNU?
TRIFERIC AVNU 1.5 MG contains IRON (FERRIC PYROPHOSPHATE CITRATE) : 1.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02515334, held by ROCKWELL MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 26-Oct-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02515334 |
|---|---|
| Brand name | TRIFERIC AVNU |
| Generic / active ingredient | IRON (FERRIC PYROPHOSPHATE CITRATE) : 1.5 MG |
| Manufacturer | ROCKWELL MEDICAL INC |
| Strength | 1.5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B03AC IRON, PARENTERAL PREPARATIONS |
| AHFS class | 20:04.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 26-Oct-2022 |
What can be used instead?
Other Canadian products sharing ATC code B03AC IRON, PARENTERAL PREPARATIONS. 5 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FERINJECT | 50 MG | DISPERSION | VIFOR (INTERNATIONAL) INC. | MARKETED | DIN 02546078 |
| FERRLECIT | 12.5 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02243333 |
| MONOFERRIC | 100 MG | SOLUTION | Pfizer Canada Ulc | MARKETED | DIN 02477777 |
| PMS-IRON SUCROSE | 20 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02502917 |
| VENOFER | 20 MG | SOLUTION | FRESENIUS MEDICAL CARE CAN INC | MARKETED | DIN 02243716 |
| DEXIRON | 50 MG | SOLUTION | AMERICAN REGENT, INC | CANCELLED POST MARKET | DIN 02205963 |
| FERAHEME | 30 MG | SOLUTION | AMAG PHARMACEUTICALS INC | CANCELLED POST MARKET | DIN 02377217 |
| INFUFER | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02221780 |
| JECTOFER 50 MG/ML | 100 MG | LIQUID | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | DIN 00001910 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.